Device Trial Radar · NCT06410313
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 15, 2024
Primary completion
Jan 30, 2027
Study completion Feb 28, 2030
Sponsor
- Lead sponsor
- Medinol Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open label, multicenter, single arm, first in human clinical study. Patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be enrolled. The patients will be treated with the ChampioNIR Stent System. All implanted patients will be followed up at 30 days and 6, 12, 24 and 36 months. The follow-up visits will include patency evaluation by duplex ultrasound
Conditions
- Superficial Femoral Artery Stenosis
- Popliteal Artery Stenosis
Interventions
ChampioNIR Ridaforolimus Eluting Peripheral Stent SystemDevice
ChampioNIR implantation in Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery disease
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary patency of the target lesionTime frame: 6 months
1 more outcomes with a free account
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Piedmont Healthcare, Inc.
Atlanta, Georgia
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.